Autoimmune Program

About cTRL Therapeutics

cTRL Therapeutics is a private, pre-clinical stage biotech developing a next-generation engineered T cell therapy platform for oncology and autoimmunity. The company's technology seeks to improve upon existing cell therapies by enhancing control over T cell activity and durability. While still in early development, its approach targets significant unmet needs in solid tumors and autoimmune disorders. As a private entity, it is likely funded by venture capital and strategic partnerships to advance its pipeline.

About Orthogen

Orthogen AG is a pioneering German biotech firm with over 25 years of experience in molecular and autologous medicine. It has developed proprietary platform technologies that harness the body's own immune mediators to address the root causes of diseases, moving beyond symptom management. The company's applications span orthopedics, pain management, veterinary medicine, aesthetics, and several autoimmune and chronic conditions, with over 400,000 treatments administered globally. Led by its founder and CEO, Dr. Peter Wehling, Orthogen operates as a private, research-driven entity aiming to shift treatment paradigms in regenerative medicine.

About Atara Biotherapeutics

Atara Biotherapeutics is a leader in allogeneic T-cell immunotherapy, focused on developing readily available, off-the-shelf cell therapies. Its landmark achievement is the European Commission approval of EBVALLO™ (tabelecleucel) for EBV+ PTLD, the first allogeneic T-cell therapy ever approved. The company's strategy centers on leveraging its proprietary EBV T-cell platform, which avoids gene editing, to build a pipeline targeting cancer and autoimmune diseases, while navigating the complex transition toward commercialization.

Therapeutic Areas

Other Autoimmune Disease (unspecified) Drugs